Collect tumor samples to guide early breast cancer recurrence care
Part of Cancer clinical trials.
This Phase 2 study tests a “precision” approach using tumor sample testing to help predict, prevent, and treat early metastatic recurrence in triple-negative or hormone-receptor–low, HER2-negative breast cancer. If you qualify, you’ll be asked to provide tumor tissue before (or in place of) standard chemotherapy, so researchers can learn which tumor features matter most.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re age 18 or older, and your breast cancer is Stage I–III (not Stage IV/metastatic).
- Your tumor must be triple-negative or hormone-receptor–low and HER2-negative based on lab testing (ER/PR/HER2 results from your pathology).
- You have not had any prior treatment for your current breast cancer (no chemo, radiation, or hormone therapy for it).
- Your primary tumor or lymph node metastasis is at least 1.5 cm (inflammatory breast cancer can qualify even if smaller).
- You can safely provide baseline tumor tissue—your doctors can access the tumor/lymph node with a procedure that’s not too risky for you.
- You have about a year or more to live (your oncologist’s estimate) and your overall health score is ECOG 0–2.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at tumor “clues” by using tissue and blood samples in people with metastatic breast cancer (with specific subtype). It aims to better understand what drives the cancer, which may help guide future treatments.
This study tracks tiny traces of cancer DNA in the blood over time to see if it can find early signs of breast cancer coming back. It looks at different types of breast cancer and at different points in a patient's treatment journey.
This study collects small tissue samples from your breast cancer before, during, and after chemotherapy and immunotherapy to identify early signs of how well the treatment is working. The goal is to better predict treatment response and improve outcomes for patients with triple-negative or high-risk hormone-positive breast cancer.
This Phase 2 study looks at how well early breast cancer shrinks with treatment and how that matches with what doctors find after surgery under the microscope. The goal is to learn better ways to predict and assess treatment success.
This trial studies early, hormone receptor–positive, HER2-negative breast cancer and looks at a group with “high clinical risk” but “low genetic (tumor) risk.” It may help researchers understand which patients may benefit most from treatment decisions guided by genetic tumor testing.
This study uses tumor genetic testing to help plan more precise treatment for people with early high-risk breast cancer. You may be asked to give a recent tumor sample so researchers can match your cancer features with the best available options.
Hear when a new Breast Cancer Recurrent trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.